Boehringer Ingelheim partners with Henke-Sass, Wolf to develop innovative needle free injection device for pigs

Ingelheim, Germany, October 27, 2020 – Boehringer Ingelheim, a global leader in animal health, partnered with Henke-Sass, Wolf to develop an innovative intramuscular needle free vaccine injection tool for pigs around weaning until the end of nursery.

This novel device will be available from December 2020 to swine producers in most countries globally under two different brands FreVAX^™ (through Boehringer Ingelheim) and EPIG^® (through Henke-Sass, Wolf).

Stephan Lange, Head of Swine, Boehringer Ingelheim Animal Health, shares: “Both FreVAX^™ and EPIG^® fulfill the desire of swine producers to ensure safety of pigs and people as well as efficacy of vaccine application by avoiding broken needles and reducing pathogen transmission while increasing vaccination compliance, animal well-being and data availability and management. Our customers will truly benefit from this innovation.”

“Combining the technical skills and experience of a leading health technology company with the expertise of the global leader in swine vaccines have led to the development of a state-of-the-art innovative device addressing farmers’ needs for safe and efficacious vaccine administration,” comments Stefan Knefel, Vice President Sales & Marketing Veterinary Products, Henke-Sass, Wolf.

FreVAX^™ and EPIG^® replace conventional needle vaccination, ensuring smooth and painless intramuscular injections of 1 or 2 ml with no recoil, low noise level and direct feedback for the user through intelligent sensors and LED alerts. These features have been incorporated to improve the vaccination experience for both the pig and the operator whilst offering vaccination compliance and reliability. In addition, the product also provides smart functions for data capture and transfer.

All this information as well as evaluation of vaccination quality can be accessed on smart phones thanks to a specifically designed app available for download from the Apple Store and Google Play Store.

Henke-Sass, Wolf

Henke-Sass, Wolf (HSW) is a mid-sized, family owned business and one of the leading medical technology companies in Germany. The company is the leading global Original Equipment Manufacturer (OEM) in the field of rigid endoscopes. Additionally, Henke-Sass, Wolf produces a wide range of industrial products, medical and dental syringes as well as innovative veterinary products. The veterinary division in particular has experienced above-average growth in recent years and continues to focus on innovative products to improve future vaccination quality and animal welfare. More than 1,500 people work for HSW and its seven subsidiary companies. The export ratio is constantly over 80 percent. For more information, visit www.henkesasswolf.de.

Boehringer Ingelheim Animal Health

The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. Across the globe, our 10,000 employees are dedicated to delivering value through innovation, thus enhancing the well-being of both.

Respect for animals, humans and the environment is at the heart of what we do. We develop solutions and provide services to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society-threatening diseases.

Boehringer Ingelheim Animal Health is the second largest animal health business in the world, with net sales of 4 billion euros in 2019 and presence in more than 150 countries. For more information visit: www.boehringer-ingelheim.com/animal-health/overview.

Boehringer Ingelheim

Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.

As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of 19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.

We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com.

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.